Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Keiko who wrote (7604)	12/29/1997 10:57:00 PM
From: Robert L. Ray	Read Replies (1) \| Respond to of 14328

I did a little searching and this was as close as I could come to the links your looking for. They're not exactly what you want though I don't think. sciam.com cholestech.com

To: Keiko who wrote (7604)	12/29/1997 10:58:00 PM
From: RICHARD LOCKIE	Respond to of 14328

Keiko: About a year ago I read about a company thats developing a silicon chip with capability of over 1000 test sights. Each sight can be sensitized to a particular medical test. IF a blood sample is applied over the sights, any matches attach to the appropriate sight. It look great to me, but I lost interest. I'm not sure I can find the name of the company. Will try! Richard Lockie

To: Keiko who wrote (7604)	12/29/1997 11:09:00 PM
From: Leslie S. Feinberg	Read Replies (2) \| Respond to of 14328

Keiko: Last Friday, on the Peter Jennings (ABC)evening news show, as I recall there was an article on this technology. It was amazing. The chip uses electronically controlled gates much like CPU chips do to control electron flow, only these gates control the movement of serum or other test fluid through a capillary system. The chips have the capacity to do up to 10,000 tests in one shot. The researcher interviewed thought the application would be in research settings initially. There was also an article in one of the magazines I read recently; though I just don't recall now which it was. Could even have been in USA Today of last week. My ever industrious wife just this morning took our past couple weeks of old news to recycle. Damn! It seemed to me the technology could have great value in a biotech research setting as opposed to a clinical setting. Hope this is of some help, wish I had paid more attention at the time (how many times have I said that). So, anyway, what's your thinking on the B's. At this low price it looks like a sure thing. These B's expire in Oct. '99? El Scripto